Abstract

We report that bacterial RNA polymerase (RNAP) is the functional cellular target of the depsipeptide antibiotic salinamide A (Sal), and we report that Sal inhibits RNAP through a novel binding site and mechanism. We show that Sal inhibits RNA synthesis in cells and that mutations that confer Sal-resistance map to RNAP genes. We show that Sal interacts with the RNAP active-center 'bridge-helix cap,' comprising the 'bridge-helix N-terminal hinge,' 'F-loop,' and 'link region.' We show that Sal inhibits nucleotide addition in transcription initiation and elongation. We present a crystal structure that defines interactions between Sal and RNAP and effects of Sal on RNAP conformation. We propose that Sal functions by binding to the RNAP bridge-helix cap and preventing conformational changes of the bridge-helix N-terminal hinge necessary for nucleotide addition. The results provide a target for antibacterial drug discovery and a reagent to probe conformation and function of the bridge-helix N-terminal hinge.

Article and author information

Author details

  1. David Degen

    Rutgers University, Piscataway, United States
    Competing interests
    David Degen, patents pending on Sal derivatives and on bridge-helix-cap target.
  2. Yu Feng

    Rutgers University, Piscataway, United States
    Competing interests
    Yu Feng, patents pending on Sal derivatives.
  3. Yu Zhang

    Rutgers University, Piscataway, United States
    Competing interests
    Yu Zhang, patents pending on Sal derivatives.
  4. Katherine Y Ebright

    Rutgers University, Piscataway, United States
    Competing interests
    Katherine Y Ebright, patent pending on bridge-helix-cap target.
  5. Yon W Ebright

    Rutgers University, Piscataway, United States
    Competing interests
    Yon W Ebright, patents pending on Sal derivatives.
  6. Matthew Gigliotti

    Rutgers University, Piscataway, United States
    Competing interests
    No competing interests declared.
  7. Hanif Vahedian-Movahed

    Rutgers University, Piscataway, United States
    Competing interests
    No competing interests declared.
  8. Sukhendu Mandal

    Rutgers University, Piscataway, United States
    Competing interests
    No competing interests declared.
  9. Meliza Talaue

    Rutgers University, Newark, United States
    Competing interests
    No competing interests declared.
  10. Nancy Connell

    Rutgers University, Newark, United States
    Competing interests
    No competing interests declared.
  11. Eddy Arnold

    Rutgers University, Piscataway, United States
    Competing interests
    No competing interests declared.
  12. William Fenical

    University of California, San Diego, La Jolla, United States
    Competing interests
    William Fenical, patent on SalA and SalB; patent pending on Sal derivatives.
  13. Richard H Ebright

    Rutgers University, Piscataway, United States
    For correspondence
    ebright@waksman.rutgers.edu
    Competing interests
    Richard H Ebright, patents pending on Sal derivatives and on bridge-helix-cap target.

Copyright

© 2014, Degen et al.

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,163
    views
  • 434
    downloads
  • 72
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. David Degen
  2. Yu Feng
  3. Yu Zhang
  4. Katherine Y Ebright
  5. Yon W Ebright
  6. Matthew Gigliotti
  7. Hanif Vahedian-Movahed
  8. Sukhendu Mandal
  9. Meliza Talaue
  10. Nancy Connell
  11. Eddy Arnold
  12. William Fenical
  13. Richard H Ebright
(2014)
Transcription inhibition by the depsipeptide antibiotic salinamide A
eLife 3:e02451.
https://doi.org/10.7554/eLife.02451

Share this article

https://doi.org/10.7554/eLife.02451

Further reading

    1. Biochemistry and Chemical Biology
    2. Structural Biology and Molecular Biophysics
    Angel D'Oliviera, Xuhang Dai ... Jeffrey S Mugridge
    Research Article

    The SARS-CoV-2 main protease (Mpro or Nsp5) is critical for production of viral proteins during infection and, like many viral proteases, also targets host proteins to subvert their cellular functions. Here, we show that the human tRNA methyltransferase TRMT1 is recognized and cleaved by SARS-CoV-2 Mpro. TRMT1 installs the N2,N2-dimethylguanosine (m2,2G) modification on mammalian tRNAs, which promotes cellular protein synthesis and redox homeostasis. We find that Mpro can cleave endogenous TRMT1 in human cell lysate, resulting in removal of the TRMT1 zinc finger domain. Evolutionary analysis shows the TRMT1 cleavage site is highly conserved in mammals, except in Muroidea, where TRMT1 is likely resistant to cleavage. TRMT1 proteolysis results in reduced tRNA binding and elimination of tRNA methyltransferase activity. We also determined the structure of an Mpro-TRMT1 peptide complex that shows how TRMT1 engages the Mpro active site in an uncommon substrate binding conformation. Finally, enzymology and molecular dynamics simulations indicate that kinetic discrimination occurs during a later step of Mpro-mediated proteolysis following substrate binding. Together, these data provide new insights into substrate recognition by SARS-CoV-2 Mpro that could help guide future antiviral therapeutic development and show how proteolysis of TRMT1 during SARS-CoV-2 infection impairs both TRMT1 tRNA binding and tRNA modification activity to disrupt host translation and potentially impact COVID-19 pathogenesis or phenotypes.

    1. Biochemistry and Chemical Biology
    2. Microbiology and Infectious Disease
    Qian Wang, Jinxin Liu ... Qian Liu
    Research Article

    Paramyxovirus membrane fusion requires an attachment protein for receptor binding and a fusion protein for membrane fusion triggering. Nipah virus (NiV) attachment protein (G) binds to ephrinB2 or -B3 receptors, and fusion protein (F) mediates membrane fusion. NiV-F is a class I fusion protein and is activated by endosomal cleavage. The crystal structure of a soluble GCN4-decorated NiV-F shows a hexamer-of-trimer assembly. Here, we used single-molecule localization microscopy to quantify the NiV-F distribution and organization on cell and virus-like particle membranes at a nanometer precision. We found that NiV-F on biological membranes forms distinctive clusters that are independent of endosomal cleavage or expression levels. The sequestration of NiV-F into dense clusters favors membrane fusion triggering. The nano-distribution and organization of NiV-F are susceptible to mutations at the hexamer-of-trimer interface, and the putative oligomerization motif on the transmembrane domain. We also show that NiV-F nanoclusters are maintained by NiV-F–AP-2 interactions and the clathrin coat assembly. We propose that the organization of NiV-F into nanoclusters facilitates membrane fusion triggering by a mixed population of NiV-F molecules with varied degrees of cleavage and opportunities for interacting with the NiV-G/receptor complex. These observations provide insights into the in situ organization and activation mechanisms of the NiV fusion machinery.